Changing treatment approaches for transplant-ineligible myeloma: DRd, BiTEs and CAR-T

Therapy Options for Transplant-ineligible Multiple MyelomaПодробнее

Treatment options for transplant-ineligible patients with multiple myelomaПодробнее

How Is CAR T-Cell Therapy Changing the Myeloma Treatment Landscape?Подробнее

Understanding CAR T Therapy: A Groundbreaking Approach to Myeloma TreatmentПодробнее

What is the Best Treatment for Transplant-ineligible Myeloma Patients: 2, 3 or 4 drugs?Подробнее

Treatment approaches for transplant-eligible and transplant-ineligbile myeloma patientsПодробнее

Treatment Strategies for Transplant Ineligible Patients with Multiple MyelomaПодробнее

CAR-T therapy vs BiTEs in multiple myeloma: current outlooks & the importance of patient selectionПодробнее

CAR-T and BiTEs – which targets belong in clinical practice?Подробнее

Treatment options for transplant-ineligble myeloma patients: the promise of combination therapiesПодробнее

Treating Transplant-Ineligible Multiple MyelomaПодробнее

Moving forward: bringing CAR-T therapy to a frontline setting in myelomaПодробнее

Is transplantation superior to CAR-T therapy in multiple myeloma?Подробнее

Transplant-Ineligible Multiple MyelomaПодробнее

CAR T-Cell Therapy in MyelomaПодробнее

Newly Diagnosed Myeloma: Transplant Ineligibility and TreatmentПодробнее

Challenges faced when treating transplant-ineligible patients with myelomaПодробнее

The future in multiple myeloma: BiTE immunotherapy, CAR-T, and immune checkpoint inhibitorsПодробнее

CAR T-cell Therapy for Multiple Myeloma 2021Подробнее